AU2023244474A1 - One-to-stop attenuated sars-cov-2 virus - Google Patents

One-to-stop attenuated sars-cov-2 virus Download PDF

Info

Publication number
AU2023244474A1
AU2023244474A1 AU2023244474A AU2023244474A AU2023244474A1 AU 2023244474 A1 AU2023244474 A1 AU 2023244474A1 AU 2023244474 A AU2023244474 A AU 2023244474A AU 2023244474 A AU2023244474 A AU 2023244474A AU 2023244474 A1 AU2023244474 A1 AU 2023244474A1
Authority
AU
Australia
Prior art keywords
cov
sars
polynucleotide
sequence
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023244474A
Other languages
English (en)
Inventor
Güliz Tuba BARUT
Martin Beer
Nadine EBERT
Nico Joel HALWE
Donata HOFFMANN
Jörg JORES
Annika KRATZEL
Fabien LABROUSSAA
Jacob SCHÖN
Volker Thiel
Bettina Salome TRÜEB
Lorenz Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Fuer Virologie und Immunologie Ivi
Universitaet Bern
RocketVax AG
Original Assignee
Inst Fuer Virologie und Immunologie Ivi
Universitaet Bern
RocketVax AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Fuer Virologie und Immunologie Ivi, Universitaet Bern, RocketVax AG filed Critical Inst Fuer Virologie und Immunologie Ivi
Priority claimed from PCT/EP2023/058069 external-priority patent/WO2023186946A1/en
Publication of AU2023244474A1 publication Critical patent/AU2023244474A1/en
Assigned to Universität Bern, ROCKETVAX AG, INSTITUT FÜR VIROLOGIE UND IMMUNOLOGIE (IVI) reassignment Universität Bern Amend patent request/document other than specification (104) Assignors: INSTITUT FÜR VIROLOGIE UND IMMUNOLOGIE (IVI), Universität Bern
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2023244474A 2022-03-28 2023-03-28 One-to-stop attenuated sars-cov-2 virus Pending AU2023244474A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22164874.4 2022-03-28
EP22164874 2022-03-28
EP22201198.3 2022-10-12
EP22201198 2022-10-12
PCT/EP2023/058069 WO2023186946A1 (en) 2022-03-28 2023-03-28 One-to-stop attenuated sars-cov-2 virus

Publications (1)

Publication Number Publication Date
AU2023244474A1 true AU2023244474A1 (en) 2024-09-12

Family

ID=92636797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023244474A Pending AU2023244474A1 (en) 2022-03-28 2023-03-28 One-to-stop attenuated sars-cov-2 virus

Country Status (9)

Country Link
US (1) US20250295757A1 (https=)
EP (1) EP4499141A1 (https=)
JP (1) JP2025513753A (https=)
KR (1) KR20240163164A (https=)
CN (1) CN119136829A (https=)
AU (1) AU2023244474A1 (https=)
CA (1) CA3244307A1 (https=)
IL (1) IL315075A (https=)
MX (1) MX2024011903A (https=)

Also Published As

Publication number Publication date
JP2025513753A (ja) 2025-04-30
IL315075A (en) 2024-10-01
KR20240163164A (ko) 2024-11-18
US20250295757A1 (en) 2025-09-25
MX2024011903A (es) 2025-01-09
EP4499141A1 (en) 2025-02-05
CA3244307A1 (en) 2023-10-05
CN119136829A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
US10421790B2 (en) Feline calicivirus vaccine
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
US20030099671A1 (en) Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
JP7053552B2 (ja) ブタ繁殖・呼吸障害症候群ワクチンウイルス
WO2022027749A1 (zh) 耐热表型稳定遗传、携带负标记的重组口蹄疫病毒无毒株及o/a型口蹄疫二价灭活疫苗
RU2687150C2 (ru) Не встречающийся в природе вирус репродуктивно-респираторного синдрома свиней (bppcc) и способы применения
CN117843733A (zh) 一种猫疱疹病毒i型hr-1毒株重组蛋白的抗原片段、截短体及其在疫苗上的应用
JP7849046B2 (ja) インフルエンザウイルスバックボーン
US20250295757A1 (en) One-to-stop attenuated sars-cov-2 virus
WO2023186946A1 (en) One-to-stop attenuated sars-cov-2 virus
CN106924726B (zh) 一种用于预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用
CN1242065C (zh) 猪繁殖与呼吸综合征重组腺病毒和疫苗
KR20220106679A (ko) 돼지 생식기 호흡기 증후군 백신 바이러스
US20260124293A1 (en) Treatment using a one-to-stop attenuated sars-cov-2 virus
CN116457010A (zh) 新的猫疱疹病毒疫苗
CA3268577A1 (en) Treatment using a one-to-stop attenuated sars-cov-2 virus
CN114958780B (zh) 一种牛Aichivirus D病毒分离株及其应用
WO2024079285A9 (en) Treatment using a one-to-stop attenuated sars-cov-2 virus
KR102402645B1 (ko) 유럽형 돼지 생식기 호흡기 증후군 바이러스의 변이주 및 이를 포함하는 백신 조성물
KR102276341B1 (ko) 유럽형 돼지 생식기 호흡기 증후군 바이러스의 제조 방법 및 이의 용도
RU2805193C1 (ru) Вакцинный вирус свиного репродуктивно-респираторного синдрома
KR100430960B1 (ko) 매우약독화된재조합일본뇌염바이러스를생성하는감염성일본뇌염바이러스cDNA클론및이의백신
CN120098937A (zh) 一株猪繁殖与呼吸综合征病毒标记弱毒疫苗株及其应用

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UNIVERSITAET BERN

Free format text: FORMER NAME(S): UNIVERSITAET BERN; INSTITUT FUER VIROLOGIE UND IMMUNOLOGIE (IVI)

Owner name: INSTITUT FUER VIROLOGIE UND IMMUNOLOGIE (IVI)

Free format text: FORMER NAME(S): UNIVERSITAET BERN; INSTITUT FUER VIROLOGIE UND IMMUNOLOGIE (IVI)

Owner name: ROCKETVAX AG

Free format text: FORMER NAME(S): UNIVERSITAET BERN; INSTITUT FUER VIROLOGIE UND IMMUNOLOGIE (IVI)